PURPOSE: Our objective was to evaluate the pharmacokinetics (PK) of doxorubicin during pregnancy compared to previously published data from non-pregnant subjects. METHODS: During mid- to late-pregnancy, serial blood and urine samples were collected over 72 h from seven women treated with doxorubicin for malignancies. PK parameters were estimated using non-compartmental techniques. Pregnancy parameters were compared to those previously reported non-pregnant subjects. RESULTS: During pregnancy, mean (±SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 ± 80 mL/min/m(2); steady-state volume of distribution (Vss), 1,132 ± 476 L/m(2); and terminal half-life (T1/2), 40.3 ± 8.9 h. The BSA-adjusted CL was significantly decreased (p < 0.01) and T1/2 was not different compared to non-pregnant women. Truncating our data to 48 h, PK parameters were: CL, 499 ± 116 ml/min/m(2); Vss, 843 ± 391 L/m(2); and T1/2, 24.8 ± 5.9 h. The BSA-adjusted CL in pregnancy compared to non-pregnant data was significantly decreased in 2 of 3 non-pregnant studies (p < 0.05, < 0.05, NS). Vss and T1/2 were not significantly different. CONCLUSIONS: In pregnant subjects, we observed significantly lower doxorubicin CL in our 72 h and most of our 48 h sampling comparisons with previously reported non-pregnant subjects. However, the parameters were within the range previously reported in smaller studies. At this time, we cannot recommend alternate dosage strategies for pregnant women. Further research is needed to understand the mechanism of doxorubicin pharmacokinetic changes during pregnancy and optimize care for pregnant women.
PURPOSE: Our objective was to evaluate the pharmacokinetics (PK) of doxorubicin during pregnancy compared to previously published data from non-pregnant subjects. METHODS: During mid- to late-pregnancy, serial blood and urine samples were collected over 72 h from seven women treated with doxorubicin for malignancies. PK parameters were estimated using non-compartmental techniques. Pregnancy parameters were compared to those previously reported non-pregnant subjects. RESULTS: During pregnancy, mean (±SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 ± 80 mL/min/m(2); steady-state volume of distribution (Vss), 1,132 ± 476 L/m(2); and terminal half-life (T1/2), 40.3 ± 8.9 h. The BSA-adjusted CL was significantly decreased (p < 0.01) and T1/2 was not different compared to non-pregnant women. Truncating our data to 48 h, PK parameters were: CL, 499 ± 116 ml/min/m(2); Vss, 843 ± 391 L/m(2); and T1/2, 24.8 ± 5.9 h. The BSA-adjusted CL in pregnancy compared to non-pregnant data was significantly decreased in 2 of 3 non-pregnant studies (p < 0.05, < 0.05, NS). Vss and T1/2 were not significantly different. CONCLUSIONS: In pregnant subjects, we observed significantly lower doxorubicin CL in our 72 h and most of our 48 h sampling comparisons with previously reported non-pregnant subjects. However, the parameters were within the range previously reported in smaller studies. At this time, we cannot recommend alternate dosage strategies for pregnant women. Further research is needed to understand the mechanism of doxorubicin pharmacokinetic changes during pregnancy and optimize care for pregnant women.
Authors: Mary F Hebert; Darcy B Carr; Gail D Anderson; David Blough; Grace E Green; Debra A Brateng; Eric Kantor; Thomas J Benedetti; Thomas R Easterling Journal: J Clin Pharmacol Date: 2005-01 Impact factor: 3.126
Authors: Jennifer L Lycette; Carrie L Dul; Myrna Munar; Donna Belle; Stephen Y Chui; Dennis R Koop; Craig R Nichols Journal: Clin Breast Cancer Date: 2006-10 Impact factor: 3.225
Authors: H Hochster; L Liebes; S Wadler; R Oratz; J C Wernz; M Meyers; M Green; R H Blum; J L Speyer Journal: J Natl Cancer Inst Date: 1992-11-18 Impact factor: 13.506
Authors: M F Hebert; T R Easterling; B Kirby; D B Carr; M L Buchanan; T Rutherford; K E Thummel; D P Fishbein; J D Unadkat Journal: Clin Pharmacol Ther Date: 2008-02-20 Impact factor: 6.903
Authors: Ira Kantrowitz-Gordon; Karen Hays; Olumide Kayode; Aditya R Kumar; Henry G Kaplan; Joel M Reid; Stephanie L Safgren; Matthew M Ames; Thomas R Easterling; Mary F Hebert Journal: Cancer Chemother Pharmacol Date: 2018-01-05 Impact factor: 3.333
Authors: Swantje Völler; Joachim Boos; Miriam Krischke; Gudrun Würthwein; Nina E Kontny; Alan V Boddy; Georg Hempel Journal: Clin Pharmacokinet Date: 2015-11 Impact factor: 6.447
Authors: Sarah A Holstein; James C Bigelow; Richard D Olson; Robert E Vestal; Gerald M Walsh; Raymond J Hohl Journal: Invest New Drugs Date: 2015-02-21 Impact factor: 3.850
Authors: Jonás Samuel Pérez-Blanco; Dolores Santos-Buelga; María Del Mar Fernández de Gatta; Jesús María Hernández-Rivas; Alejandro Martín; María José García Journal: Br J Clin Pharmacol Date: 2016-09-06 Impact factor: 4.335